Expert Interview
A Third Opinion: Investigating the potential of BCMA CAR-T therapies in AL Amyloidosis, including NXC-201 by Immix Biopharma/Nexcella
Ticker(s): IMMX, BMY, JNJInstitution: Hadassah Medical Center, Hebrew University of Jerusalem
Associate Professor of Pediatrics and Director of the Department of Bone Marrow Transplantation and Cancer Immunotherapy at Hadassah Medical Center, specializing in pediatric hematology-oncology and rare genetic immunodeficiencies.
Serves as a key leader in immunotherapy and gene therapy programs, mentoring fellows and coordinating international collaborations for rare disease treatments.
Leads research on novel CAR-T therapies and genetic correction for primary immunodeficiencies, with over 150 publications advancing pediatric transplant outcomes.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
